Postoperative bile leak Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative bile leak Median compared with non‐fibrin‐based haemostatic agents (very low certainty).
1 finding from 1 review
Serious adverse events Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes serious adverse events Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Postoperative transfusion Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative transfusion Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Reoperation Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes reoperation Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Postoperative bile leak Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative bile leak Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Perioperative mortality · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes perioperative mortality Median compared with non‐fibrin‐based haemostatic agents (very low certainty).
1 finding from 1 review
Serious adverse events Median · adults undergoing liver resection for cancer or benign disease
Fibrin‐based haemostatic agents showed no clear difference in serious adverse events Median compared with non‐fibrin‐based haemostatic agents (low certainty).
1 finding from 1 review
Postoperative transfusion Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative transfusion Median compared with non‐fibrin‐based haemostatic agents (very low certainty).
1 finding from 1 review
Reoperation Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes reoperation Median compared with non‐fibrin‐based haemostatic agents (very low certainty).
1 finding from 1 review
Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Health‐related quality of life ‐ all trials Higher scores indicate improved health‐related quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in hepatic encephalopathy ‐ total number compared with non‐absorbable disaccharide (low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).
1 finding from 1 review
Blood ammonia measured in μg/mL at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Number Connection Test A, assessed using: seconds (1 trial) or Z‐score (1 trial) at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin plus non‐absorbable… probably leads to lower mortality ‐ total number compared with non‐absorbable disaccharides alone (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin plus non‐absorbable… may leads to lower hepatic encephalopathy ‐ total number compared with non‐absorbable disaccharides alone (low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
1 finding from 1 review
Blood ammonia measured in μg/mL at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review